Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature

By                    

Oncology Letters, Vol. 10, Iss. 6, 2015-01 ,pp. : 3749-3755

Spandidos Publications

Access to resources Recommend Favorite

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1432-1438

Spandidos Publications

Access to resources Recommend Favorite

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

By Qvortrup Camilla   Jensen Benny Vittrup   Jorgensen Trine Lembrecht   Nielsen Dorte   Bjerregaard Jon Kroll   Pfeiffer Per  

Acta Oncologica, Vol. 49, Iss. 6, 2010-08 ,pp. : 833-836

Informa Healthcare

Access to resources Recommend Favorite

Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment

By Perrin Christophe   Fabre Cédric   Raoul Jean-Luc   Boucher Eveline  

Acta Oncologica, Vol. 45, Iss. 8, 2006-12 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

By Iacovelli Roberto   Palazzo Antonella   Mezi Silvia   Morano Federica   Naso Giuseppe   Cortesi Enrico  

Acta Oncologica, Vol. 51, Iss. 7, 2012-09 ,pp. : 873-879

Informa Healthcare

Access to resources Recommend Favorite